BSE filing, NSE: ISHITADR. Summary written from the filing by ALFA Finder's alert engine.
Ishita Drugs & Industries Ltd: key numbers
- Share price
- ₹74.60
- Market cap
- ₹22.31 Cr
- Revenue (annual)
- ₹14.66 Cr
- Net profit (annual)
- ₹0.78 Cr
- P/E (TTM)
- 31.6×Sector 46.1×
- Promoter holding
- 50.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ishita Drugs & Industries Ltd
All →Ishita Drugs & Industries Board Meeting Date
Ishita Drugs & Industries will hold a board meeting on 03/11/2026 to approve Q1 FY2027 unaudited results. The filing is a prior intimation under Regulation 29 of SEBI LODR.
Ishita Drugs & Industries Management Change
Ishita Drugs and Industries Limited has re-appointed Mrs. Abha Agrawal as a Non-Executive Non-Independent Director. The company also re-appointed M/s. Jaymin Shah & Associates as Statutory Auditors.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd has re-appointed M/s. Jaymin Shah & Associates as its Statutory Auditor from the 33rd to the 34th AGM.
Ishita Drugs & Industries Annual General Meeting
Ishita Drugs & Industries Ltd. held its 33rd Annual General Meeting on September 30, 2026. The meeting covered financial statements, auditor appointments, and director re-appointment.
Ishita Drugs & Industries Debt & Borrowing: ₹11.75 Cr
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
- Value
- ₹11.75 Cr
Ishita Drugs & Industries Board Meeting Date
Ishita Drugs & Industries Ltd will hold a board meeting on September 22, 2026. The meeting will consider raising funds through working capital and term loans.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.